Cervical Cancer Clinical Trial
Official title:
Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making
Preventing cervical cancer is a public health concern. Since 2006 a quadrivalent vaccine for
young women nine to twenty six years of age has been available to protect against the human
papillomavirus (HPV) and to prevent some types of cervical cancer (Gardasil). The vaccine is
an important health promotion tool to address the widespread prevalence of HPV and cervical
cancer, but not all eligible young women receive the vaccine. The vaccine is most effective
when administered to young women before their sexual debut. When the vaccine is given to
young women less than 18 years of age, parental permission is required. This permission is
usually provided by the young woman's mother. Understanding predictors of a mother's
decision for her minor daughter to receive the HPV vaccine will inform interventions that
seek to increase the number of young women who receive the vaccine.
The study will focus on mothers and their adolescent daughters between 13-17 years of age.
We hypothesize that the Expanded Theory of Planned Behavior will explain a mother's decision
to choose the HPV vaccine for her daughter.
Research Questions include: 1)What TPB variables predict a mother's decision to choose HPV
vaccine for her daughter? 2)What variables predict the strength of a daughter's influence on
the mother's decision to choose HPV vaccine for her daughter? 3) What are the relationships
between the mothers' and daughters' scores on the variables related to the decision to
choose HPV vaccine? 4) How do the mothers and daughters who chose to receive the HPV vaccine
differ descriptively from those mothers and daughters who do not choose to receive the HPV
vaccine?
Preventing cervical cancer is a public health concern. Since 2006 a quadrivalent vaccine for
young women nine to twenty six years of age has been available to protect against the human
papillomavirus (HPV) and to prevent some types of cervical cancer (Gardasil). The vaccine is
an important health promotion tool to address the widespread prevalence of HPV and cervical
cancer, but not all eligible young women receive the vaccine. The vaccine is most effective
when administered to young women before their sexual debut. When the vaccine is given to
young women less than 18 years of age, parental permission is required. This permission is
usually provided by the young woman's mother. Understanding predictors of a mother's
decision for her minor daughter to receive the HPV vaccine will inform interventions that
seek to increase the number of young women who receive the vaccine.
Health behavior theories, such as the Theory of Planned Behavior (TPB), indicate the factors
and mechanisms that predict health promotion decisions and activities. TPB provides a direct
statistical model through which variables related to health behaviors can be measured and
evaluated, and will be used to guide the proposed study.
The study will focus on mothers and their adolescent daughters between 13-17 years of age.
The normative changes and realignments in the parent child relationship that arrive with the
onset of adolescence, coincide with greater adolescence behavioral autonomy, and influence
over parental decisions related to the adolescent. Thus, we expanded the TPB to include the
influence of the adolescent on the mother's decision for her daughter to receive the HPV
vaccine.
Hypothesis: We hypothesize that the Expanded Theory of Planned Behavior will explain a
mother's decision to choose the HPV vaccine for her daughter.
Research Questions:
RSQ1: What TPB variables predict a mother's decision to choose HPV vaccine for her daughter?
RSQ2: What variables predict the strength of a daughter's influence on the mother's decision
to choose HPV vaccine for her daughter?
RSQ3: What are the relationships between the mothers' and daughters' scores on the variables
related to the decision to choose HPV vaccine?
RSQ4: How do the mothers and daughters who chose to receive the HPV vaccine differ
descriptively from those mothers and daughters who do not choose to receive the HPV vaccine?
Data will be analyzed using path analysis, multiple regression, and analysis of variance.
The model demonstrates multiple potential influences on the mother's decision to choose the
HPV vaccine for her daughter, and all influences are potential targets for family teaching
interventions and tailored social marketing. Further study will be needed to determine how
well the model applies to various family types and diverse cultures and nationalities.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |